Comparison of microparticle enzyme and fluorescence polarization immunoassays in pediatric patients not receiving Digoxin

Michael Chicella, Bill Branim, Kelley Lee, Stephanie Phelps

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Previously, investigators have measured endogenous digoxin-like immunoreactive substances (DLIS) in pediatric patients. Digoxin-like immunoreactive substances may cross-react with digoxin assays to produce false-positive digoxin concentrations; hence, the validity of digoxin concentrations in pediatric patients is questionable. The authors compared the presence and magnitude of apparent DLIS using the microparticle enzyme immunoassay (MEIA) AxSYM Digoxin II and the fluorescence polarization immunoassay (FPIA) TDx Digoxin II, in the serum of 80 pediatric patients who were hospitalized with normal serum creatinine but had not been administered digoxin. Patients ranged in age from 1 day to 16 years (mean age, 4.96 ± 5.17 years). Serum creatinine and total bilirubin were 0.5 ± 0.18 mg/dl and 1.3 ± 0.17 mg/dl, respectively. Forty-eight percent of MEIA samples and 79% of FPIA samples had measurable DLIS values. Digoxin-like immunoreactive substance concentrations for the MEIA (0.07 ± 0.09 ng/ml) and FPIA assays (0.1 ± 0.1 ng/ml) were statistically different (p = 0.01); however, no sample had a DLIS value >0.38 ng/ml. A poor correlation was noted between patient age, serum creatinine, total bilirubin, and DLIS concentration. The MEIA and FPIA assays effectively minimized DLIS cross-reactivity making both technologies clinically acceptable for serum digoxin measurement in pediatric patients with normal serum creatinine and total bilirubin.

Original languageEnglish (US)
Pages (from-to)347-351
Number of pages5
JournalTherapeutic Drug Monitoring
Volume20
Issue number3
DOIs
StatePublished - Jun 1998

Fingerprint

Fluorescence Polarization Immunoassay
Pediatrics
Digoxin
Fluorescence
Polarization
Enzymes
Immunoenzyme Techniques
Creatinine
Serum
Bilirubin
Assays
digoxin-like factors
Research Personnel
Technology

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Pharmacology
  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

Comparison of microparticle enzyme and fluorescence polarization immunoassays in pediatric patients not receiving Digoxin. / Chicella, Michael; Branim, Bill; Lee, Kelley; Phelps, Stephanie.

In: Therapeutic Drug Monitoring, Vol. 20, No. 3, 06.1998, p. 347-351.

Research output: Contribution to journalArticle

@article{ab26878e32814064bf8fbdc34eefbb59,
title = "Comparison of microparticle enzyme and fluorescence polarization immunoassays in pediatric patients not receiving Digoxin",
abstract = "Previously, investigators have measured endogenous digoxin-like immunoreactive substances (DLIS) in pediatric patients. Digoxin-like immunoreactive substances may cross-react with digoxin assays to produce false-positive digoxin concentrations; hence, the validity of digoxin concentrations in pediatric patients is questionable. The authors compared the presence and magnitude of apparent DLIS using the microparticle enzyme immunoassay (MEIA) AxSYM Digoxin II and the fluorescence polarization immunoassay (FPIA) TDx Digoxin II, in the serum of 80 pediatric patients who were hospitalized with normal serum creatinine but had not been administered digoxin. Patients ranged in age from 1 day to 16 years (mean age, 4.96 ± 5.17 years). Serum creatinine and total bilirubin were 0.5 ± 0.18 mg/dl and 1.3 ± 0.17 mg/dl, respectively. Forty-eight percent of MEIA samples and 79{\%} of FPIA samples had measurable DLIS values. Digoxin-like immunoreactive substance concentrations for the MEIA (0.07 ± 0.09 ng/ml) and FPIA assays (0.1 ± 0.1 ng/ml) were statistically different (p = 0.01); however, no sample had a DLIS value >0.38 ng/ml. A poor correlation was noted between patient age, serum creatinine, total bilirubin, and DLIS concentration. The MEIA and FPIA assays effectively minimized DLIS cross-reactivity making both technologies clinically acceptable for serum digoxin measurement in pediatric patients with normal serum creatinine and total bilirubin.",
author = "Michael Chicella and Bill Branim and Kelley Lee and Stephanie Phelps",
year = "1998",
month = "6",
doi = "10.1097/00007691-199806000-00018",
language = "English (US)",
volume = "20",
pages = "347--351",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Comparison of microparticle enzyme and fluorescence polarization immunoassays in pediatric patients not receiving Digoxin

AU - Chicella, Michael

AU - Branim, Bill

AU - Lee, Kelley

AU - Phelps, Stephanie

PY - 1998/6

Y1 - 1998/6

N2 - Previously, investigators have measured endogenous digoxin-like immunoreactive substances (DLIS) in pediatric patients. Digoxin-like immunoreactive substances may cross-react with digoxin assays to produce false-positive digoxin concentrations; hence, the validity of digoxin concentrations in pediatric patients is questionable. The authors compared the presence and magnitude of apparent DLIS using the microparticle enzyme immunoassay (MEIA) AxSYM Digoxin II and the fluorescence polarization immunoassay (FPIA) TDx Digoxin II, in the serum of 80 pediatric patients who were hospitalized with normal serum creatinine but had not been administered digoxin. Patients ranged in age from 1 day to 16 years (mean age, 4.96 ± 5.17 years). Serum creatinine and total bilirubin were 0.5 ± 0.18 mg/dl and 1.3 ± 0.17 mg/dl, respectively. Forty-eight percent of MEIA samples and 79% of FPIA samples had measurable DLIS values. Digoxin-like immunoreactive substance concentrations for the MEIA (0.07 ± 0.09 ng/ml) and FPIA assays (0.1 ± 0.1 ng/ml) were statistically different (p = 0.01); however, no sample had a DLIS value >0.38 ng/ml. A poor correlation was noted between patient age, serum creatinine, total bilirubin, and DLIS concentration. The MEIA and FPIA assays effectively minimized DLIS cross-reactivity making both technologies clinically acceptable for serum digoxin measurement in pediatric patients with normal serum creatinine and total bilirubin.

AB - Previously, investigators have measured endogenous digoxin-like immunoreactive substances (DLIS) in pediatric patients. Digoxin-like immunoreactive substances may cross-react with digoxin assays to produce false-positive digoxin concentrations; hence, the validity of digoxin concentrations in pediatric patients is questionable. The authors compared the presence and magnitude of apparent DLIS using the microparticle enzyme immunoassay (MEIA) AxSYM Digoxin II and the fluorescence polarization immunoassay (FPIA) TDx Digoxin II, in the serum of 80 pediatric patients who were hospitalized with normal serum creatinine but had not been administered digoxin. Patients ranged in age from 1 day to 16 years (mean age, 4.96 ± 5.17 years). Serum creatinine and total bilirubin were 0.5 ± 0.18 mg/dl and 1.3 ± 0.17 mg/dl, respectively. Forty-eight percent of MEIA samples and 79% of FPIA samples had measurable DLIS values. Digoxin-like immunoreactive substance concentrations for the MEIA (0.07 ± 0.09 ng/ml) and FPIA assays (0.1 ± 0.1 ng/ml) were statistically different (p = 0.01); however, no sample had a DLIS value >0.38 ng/ml. A poor correlation was noted between patient age, serum creatinine, total bilirubin, and DLIS concentration. The MEIA and FPIA assays effectively minimized DLIS cross-reactivity making both technologies clinically acceptable for serum digoxin measurement in pediatric patients with normal serum creatinine and total bilirubin.

UR - http://www.scopus.com/inward/record.url?scp=0031810663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031810663&partnerID=8YFLogxK

U2 - 10.1097/00007691-199806000-00018

DO - 10.1097/00007691-199806000-00018

M3 - Article

VL - 20

SP - 347

EP - 351

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 3

ER -